GlaxoSmithKline, the UK-based pharmaceutical company, plans to channel $100m by the end of next year into a neuroscience research centre in China which will become pivotal to its global drug development.
Ahead of GSK's first presentation focused on its emerging neuroscience pipeline drugs which takes place today, Moncef Slaoui, the chairman of research and development, has said the company will build a centre in Shanghai responsible for all the company's work on neurodegenerative diseases.
